We offer our registered users tailored information, free online courses and exclusive content.
English with simultaneous translation from/to Portuguese
For registration, accommodation and any logistic inquiry please contact:
Meridiano Congress International
Congress Manager: Federica Russetti
T +39 06 88 595 209 - F +39 06 88 595 234
This meeting will be live streamed
When: 30 May 2017
Where:
Time: 8:45 am local time
Need help? Watch this video to understand how to join the live stream.
Therapy with recombinant human Growth Hormone (rhGH) is widely available and has been the most important treatment for several growth disorders in childhood since 1985. Great efforts have been made, through single centre studies and international multi-centre studies, to collect data on patient compliance and long-term safety. Both issues are still points of discussion worldwide.
Achieving consensus on compliance and long-term safety is not straightforward when considering the magnitude of data required, the heterogeneity of growth disorders treated with rhGH, as well as the varying rhGH dosages and devices. Parents and caregivers involved in the care of these children still face doubts about optimal follow-up treatment.
This workshop will offer the most updated scientific evidence on long-term safety of rhGH therapy and look at how to assess and improve patient compliance. Milestones and new insight on these issues will be discussed by international experts who will use the opportunity to improve how rhGH therapy is managed in childhood.
• Assess and improve adherence in patients on rhGH treatment
• Manage patients with growth hormone disorders (GHD) according to most updated data on long-term safety
• Manage patients with Turner Syndrome on rhGH therapy
• Assess effectiveness of rhGH therapy in SGA patients
• Arrange transition of GHD patients from childhood to adulthood
EXCEMED designed this programme with the endorsement of the Brasilian Society of Paediatrics (SBP - Sociedade Brasileira de Pediatria). 
08.45 Welcome and introduction
P.F. Collett-Solberg (Brazil)
09.00 L1: How to assess and improve adherence in patients on rhGH therapy VIDEO LECTURE
P.F. Collett-Solberg (Brazil)
09.30 L2: Long-term effect and safety of rhGH in Turner syndrome
P. Chatelain (France)
10.00 L3: Children small for gestational age and rhGH therapy: safety and effect on cardiometabolic risk
A.C.S. Hokken-Koelega (The Netherlands)
10.30 Panel discussion
11.00 Coffee break
11.30 L4: Long-term safety of rhGH therapy in children with GH deficiency
L. Sävendahl (Sweden)
12.00 L5: Transitional period: differences of GH treatment follow-up from childhood to adulthood VIDEO LECTURE
A.A.L. Jorge (Brazil)
12.30 L6: Personalized approach to rhGH treatment: potential impact on outcome, adherence and safety VIDEO LECTURE
F. Cassorla (Chile)
13.00 Panel discussion
13.30 Lunch
14.30 Three parallel working groups: Problem solving of clinical cases
Case study: Boy, healthy but referred due to slow growth in recent years
Case study: 5 11/12 yrs old males referred for short stature
15.30 Discussion in plenary session of clinical cases previously discussed by the working groups
16.30 Concluding remarks
P.F. Collett-Solberg (Brazil)
16.45 End of the workshop
